According to a report in a Chinese newspaper, China is planning to spend more than CNY 10 billion (US$1.5 billion) to support the development of new drugs between 2011 and 2016. Biotechnology was identified as one of seven emerging industries that China will use to spearhead the next big step in its economic development.
- INICIO
-
Genéricos
Novedades
- US generics launch and approval for Dr Reddy’s and Lupin
- Five Chinese companies join UN’s MPP for Covid-19 medicines
- South Korean companies to make generic Bridion and COVID-19 drugs
- Revlimid (lenalidomide) generics launch across Europe
-
Biosimilares
Novedades
- New insulin glargine and potential adalimumab interchangeable biosimilars
- Biosimilar advances for Alvotech-Teva and setback for Biocon Biologics
- Advances for Bio-Thera’s secukinumab and mepolizumab copy biologicals
- FDA and EMA file acceptance of Biogen’s tocilizumab biosimilar
Investigación
- EE.UU. frente a Alemania y Suiza: El mercado estadounidense de biosimilares se queda atrás con precios más altos
- Drug survival of adalimumab biosimilars in psoriasis treatment in Spain
- Pegfilgrastim biosimilars in US supportive oncology
- Investigating cell, tissue and gene therapy products and their regulation
General
- Canada’s Ontario introduces biosimilars switching policy
- Hechos clave en la regulación de la aprobación de biosimilares en Brasil
- La provincia canadiense de Saskatchewan introduce una política de switching de biosimilares
- A Canadian gastro-enterologist’s view on advising on biosimilars
- MORE EDITORIAL SECTIONS
- Search
Post your comment